Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors

By Thomas Moehler, MD, PhD,  Cheryl Askew, PhD, Sven Tang, MD, A. Philippe Chahinian, MD, Sheena Demelo, MD, and Dolores Tarabaric, MD

Oncologists and their patients have had reason recently to be encouraged by the launch of immune checkpoint inhibitors (ICIs) for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer. These novel agents activate the human immune response against antigens expressed on tumor cells, and the science has generated excitement among physicians, patients, the media and researchers.